Clinical Trials Logo
  1. Home
  2. Non-squamous NSCLC
  3. NCT03755869

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Non-squamous NSCLC Clinical Trial

Official title:
An Open, Single-arm, Multi-center Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line Chemotherapy

Clinical Trial Summary

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase. In the phase III study, Patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib (12mg, po. qd. on day 1to14 of a 21-day cycle) or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months.

Clinical Trial Description

It is an open, single-arm, multi-center clinical trial conducted in China, and plan to Recruiting103 patients who were progressed after first line systemic therapy and refused/can't tolerate chemotherapy. Patents receive 12mg anlotinib orally daily on day 1to 14 of a 21-day cycle until progression of disease, assess safety and efficacy of the drug. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03755869
Study type Interventional
Source First Affiliated Hospital Xi'an Jiaotong University
Contact enxiao li, professor
Phone 0086-13992819833
Email doclienxiao@sina.com
Status Recruiting
Phase Phase 4
Start date November 29, 2018
Completion date December 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04447118 - Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy Phase 3
Active, not recruiting NCT04413201 - AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC Phase 4
Completed NCT05261438 - Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Withdrawn NCT04466917 - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer Phase 3
Not yet recruiting NCT05782426 - Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC Phase 2
Recruiting NCT05751187 - Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients Phase 2
Terminated NCT02454842 - Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients Phase 2
Not yet recruiting NCT06206850 - Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib Phase 2